Gas tamponade is more effective for RRD

Article

Using a gas tamponade, compared to an air tamponade, is more effective when treating rhegmatogenous retinal detachment (RRD).

Using a gas tamponade, compared to an air tamponade, is more effective when treating rhegmatogenous retinal detachment (RRD).

A team led by Dr H Stevie Tan, Academic Medical Center, University of Amsterdam, The Netherlands, examined the records of 524 cases of 523 patients that experienced primary vitrectomy for RRD with air or sulphur hexafluoride with a follow-up of at least three months. Cases with inferior retinal breaks were excluded from the study.

Of the patients included in the studied, 318 were treated with gas and 128 were treated with air. Eyes treated with air and gas had 81% and 86.9% chance of primary success, respectively.

A confounding factor was the involvement of lower retinal quadrants in the retinal detachment (RD). After this confounder was corrected the comparison between air and gas tamponade was statistically significant with regards to success rate.

Overall, gas tamponades are superior to air tamponades in RD cases with involvement of the lower quadrants. Air tamponades should only be used in RDs that are restricted to the superior quadrants.

The abstract can be found in the British Journal of Ophthalmology.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.